Clinical Trials Logo

Moderate Alzheimer's Disease clinical trials

View clinical trials related to Moderate Alzheimer's Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT03959553 Withdrawn - Clinical trials for Moderate Alzheimer's Disease

GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for moderate Alzheimer's disease (AD). GV1001 has been shown to inhibit neurotoxicity, apoptosis, and the production of reactive oxygen species induced by amyloid beta in neural stem cells by mimicking the extra-telomeric functions of human telomerase reverse transcriptase (hTERT). In nonclinical studies, using both mild (early stage) and severe (late stage) AD mouse models, GV1001 has been shown to improve cognitive function and memory, as well as significantly reduce the amount of amyloid beta and tau proteins. The multifunctional effect of GV1001 makes it a promising therapeutic option for the treatment for AD.

NCT ID: NCT00423228 Completed - Clinical trials for Moderate Alzheimer's Disease

Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease

BRAINz
Start date: February 2007
Phase: N/A
Study type: Interventional

Alzheimer's disease is characterised by memory loss and difficulties with thinking. These problems may be due to a deficiency in a brain chemical called acetylcholine. Acetylcholine helps transmit messages between nerve cells. Acetylcholine is degraded by an enzyme called "acetylcholinesterase". ZT-1 is a new drug derived from a plant extract already used in China for memory disorders, which blocks the action of the enzyme and restores adequate levels of acetylcholine. This study will test the safety and efficacy of ZT-1 in the treatment of patients with Alzheimer's disease. BRAINz stands for Better Recollection for Alzheimer's patients with the Implant of ZT-1.